MDxHealth SA announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Coverage Determination (LCD) for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer that covers the indication for SelectMDx® for Prostate Cancer test. The foundational LCD identifies evidence supporting the clinical utility of SelectMDx test and, when the LCD becomes effective on July 3, 2022, is expected to support coverage of test for qualified Medicare patients throughout the United States.